Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cellion Biomed Inc. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is assigned to 1 distinct examiner, MOU, LIYUAN, who is the busiest examiner with 1 pending office action. The prosecution is occurring within 1 distinct art unit, reflecting a focused technical area.
The portfolio's current activity is highly concentrated, as shown by the 1 distinct examiner and 1 distinct art unit. For a practitioner, this means that the 1 pending office action is the only active matter in the portfolio. MOU, LIYUAN is the sole examiner involved, so the prosecution strategy is focused on his review of the 1 pending office action. The 1 distinct art unit indicates that the technology is within a specific niche of Biotechnology & Pharmaceuticals.
This narrow focus means that the portfolio's immediate success is tied to the outcome of this single office action. There are no other active examiners or art units to manage, which simplifies the prosecution process. The 1 pending office action is the only current hurdle for the portfolio's active applications. Practitioners can focus their resources on the specific history of MOU, LIYUAN to optimize the response to the 1 pending office action. While this concentration reduces administrative complexity, it also means the portfolio lacks the risk mitigation of multiple active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16964752 | COMPOSITION FOR TREATING FIBROTIC DISEASES, COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16964752 | COMPOSITION FOR TREATING FIBROTIC DISEASES, COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | MOU, LIYUAN | 1628 | §103DP | Final Rejection | — | Pending | May 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellion Biomed Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Liyuan Mou has the most, with 1 of Cellion Biomed Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
